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We have shown that high dose conformal radiation combined with chemotherapy appears to pro-
long the survival of patients with unresectable intrahepatic cancers. The ability to safely deliver
higher doses is primarily limited by the development of radiation-induced liver disease, character-
ized by venous occlusion. In this study, we investigated whether portal venous perfusion measured
prior to the end of radiation therapy RT together with dose could predict liver venous perfusion
dysfunction after treatment. Ten patients with unresectable intrahepatic cancer participated in an
IRB-approved computer tomography CT perfusion study. Hepatic arterial and portal vein perfu-
sion distributions were estimated by using dynamic contrast enhanced CT and the single compart-
mental model. Scans were obtained at four time points: prior to treatment, after 15 and 30 fractions
of 1.5 Gy treatments, and one month following the completion of RT. Multivariant linear regression
was used to determine covariances among the first three time point measurements plus dose for
prediction of the post RT measurement. The reduction in the regional venous perfusion one month
following RT was predicted by the local accumulated dose and the change in the regional venous
perfusion after 30 fractions F=90.6, p0.000 01. Each Gy produced an approximately 1.2% of
reduction in the venous perfusion. This local dose and venous perfusion model has the potential to
predict individual sensitivity to radiation. This is the first step toward developing a method to
deliver higher and potentially more curative radiation doses to the patients who can safely receive
these higher doses. © 2007 American Association of Physicists in Medicine.
DOI: 10.1118/1.2431081
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Approximately two thirds of patients with intrahepatic can-
cer present with unresectable disease. Our recent study
shows that high dose conformal radiation combined with
chemotherapy appears to prolong the survival of patients
with unresectable intrahepatic cancers.1 However, attempts
to increase radiation dose still further have been limited by
the development of radiation-induced liver disease RILD.2
Symptoms generally occur 2 weeks to 2 months following
completion of radiation therapy RT and include tender
hepatomegaly and weight gain secondary to ascites. Labora-
tory findings include elevations of alkaline phosphatase,
transaminases, and bilirubin. The clinical outcome ranges
from mild, reversible damage to death.3–5 The pathology of
RILD is veno-occlusive disease, which is characterized by
thrombosis within the central veins of the liver producing
“post” hepatic congestion.6 The pathological changes may be
present in the entire liver rarely, a lobe, or a fraction of it.
604 Med. Phys. 34 „2…, February 2007 0094-2405/2007/34Efforts to develop models to estimate the likelihood of
developing RILD have been based primarily on the planned
radiation dose distribution for the normal liver, expressed as
a dose volume histogram. The ability to predict RILD is
improved by including clinical factors.4,7–12 These analyses
have demonstrated that increasing mean liver dose correlates
with the likelihood of developing RILD, and that the liver is
reasonably well modeled as a parallel organ. This means that
significant damage to a portion of the liver may not lead to
RILD as long as a sufficient volume of liver remains undam-
aged and thus can carry out normal liver function. While
these models have permitted the safe delivery of far higher
doses of radiation than have previously been possible, they
also suggest that there is a broad range of individual patient
sensitivity that is not reflected by predictions made solely
based on the physical dose distribution or general clinical
features. If individual patient sensitivity could be better esti-
mated before or during a course of treatment, it might permit
higher doses of radiation to be delivered safely to the tumors
of patients whose liver is relatively radiation resistant, thus
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challenge to developing such an approach is that the deter-
mination of risk would need to be made before the end of the
course of treatment, while the patient is still asymptomatic.
As the basic pathophysiology of RILD is venous occlu-
sion, we developed the hypothesis that early monitoring of
venous perfusion would have the potential to select patients
with preclinical signs of perfusion changes prior to the onset
of symptomatic radiation-induced injury. As a first step in
testing this hypothesis, we prospectively evaluated such
changes in regional perfusion as a function of the dose de-
livered in patients treated with high dose focal radiotherapy.
We hypothesized that regional perfusion dysfunction one
month after the completion of RT could be predicted by the
radiation dose and perfusion measured prior to the end of
treatment.
MATERIALS AND METHODS
Patients
Ten patients with unresectable intrahepatic cancer one
with hepatocellular carcinoma, four with cholangiocarci-
noma, and five with colorectal carcinoma metastatic to the
liver participated in an IRB-approved liver computer tomog-
raphy CT perfusion study Table I. All patients had signed
written consent prior to enrollment. All patients were treated
using three-dimensional conformal RT techniques. All pa-
tients were treated on our institution review board-approved
prospective treatment protocol, which has been described in
detail previously.1 Briefly, radiation was delivered twice
daily in 10–11 fractions/week, 1.5 Gy/fraction, with a mini-
TABLE I. Patients information.
Sex/age
DCE CT
scan 1
DCE CT
scan 2
DCE CT
scan 3
DCE CT
scan 4
1 M/51 Cholangio Prior to RT 22.5 Gy 49.5 Gy 1 month after
78 Gy
2 M/80 mets Prior to RT 22.5 Gy 43.5 Gy 1 month after
49.5 Gy
3 F/58 Cholangio Prior to RT 21 Gy 43.5 Gy 1 month after
60 Gy
4 M/35 Hepato Prior to RT a 42 Gy 1 month after
48 Gy
5 F/73 Cholangio Prior to RT 24 Gy 46.5 Gy 1 month after
76.5 Gy
6 M/72 Mets Prior to RT a 49.5 Gy 1 month after
67.5 Gy
7 F/55 Mets Prior to RT 21 Gy 45 Gy 1 month after
72 Gy
8 M/57 Mets Prior to RT 18 Gy 45 Gy 1 month after
67.5 Gy
9 M/74 Mets Prior to RT a 43.5 Gy 1 month after
75 Gy
10 M/74 Cholangio Prior to RT 22.5 Gy 46.5 Gy 1 month after
54 Gy
aDCE CT scans were failed. The radiation doses listed in Table I correspond
to what dose had been given when CT scans were performed.mal daily interfraction interval of 4–6 h. The median dose of
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rent continuous infusion hepatic artery floxuridine was used
as a radiation sensitizer for the first 4 weeks of RT.
Image acquisition
Patients were imaged, in their treatment positions, on a
high-speed multidetector computed tomography CT system
Lightspeed, General Electric, Milwaukee, WI. To reduce
breathing-related motion artifacts during scan acquisition, an
active breathing control ABC device Vmax, Sensormed-
ics, Yorba Linda CA was used to assist in briefly suspending
breathing at normal expiration.13 Axial planes within the
liver were selected to encompass the entrance of the portal
vein into the liver, the hepatic artery, and, if possible, a por-
tion of the tumor within the scanning window of the CT
detector array. Imaging was performed on each patient at
four time points: prior to RT, after receiving approximately
15 and 30 fractions of 1.5 Gy treatment, and one month fol-
lowing the completion of RT. The intermediate scan times
correspond to 1.5 weeks and 3 weeks excluding the two-
week break of treatment, at which times the tumors received
cumulative doses of 22 Gy and 45 Gy, respectively.
Using the multidetector scanner, dynamic contrast en-
hanced DCE CT data were acquired. Briefly, after estab-
lishing a precontrast baseline scan, an extended cine series of
images was obtained that lasted 120 seconds after contrast
injection, using multiple breath hold intervals under the aid
of an ABC system.13 During the first 90 seconds, image vol-
umes were acquired every second, followed by three sets of
three one-second images that were 9 seconds apart left panel
of Fig. 1. This produced a series of 99 volume image data
sets, each covering the entire liver in the axial plane and
extending over a 2 cm slab in the cranial-caudal direction
covering the regions of interest described above. As the liver
position is not perfectly reproduced between breath holds,
we aligned the images using an intensity-based limited de-
gree of freedom automated alignment, which finds the opti-
mal fit by maximizing mutual information within a limited
range of rigid body transformations right panel of Fig. 1.
Perfusion computation
Hepatic perfusion was estimated using a single compart-
mental model with dual input functions from the artery and
portal vein,14 similar to those used previously to analyze
liver perfusion with dynamic positron emission tomography,
CT, and MRI data.15–18 In this model, the liver tissue, includ-
ing the cells, space of Disse extravascular space, and sinu-
soids, is considered to be a single compartment. The blood
flows in from two sources the hepatic artery and portal
vein, travels through the sinusoids and space of Disse, and
flows out to the central vein. Using pharmacokinetics, a
change in the contrast concentration of liver parenchyma is
given by the differential equation as
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dt
=
1
1 − Hct
kaCat − a + kpCpt − p − K2Clt ,
1
where Cl ,Ca, and Cp are concentrations of the contrast agent
in the respective liver parenchyma, artery, and portal vein, ka
and kp are the transfer constants of the contrast agent from
respective arterial and portal venous plasma to liver paren-
chyma, K2 is the rate of the contrast agent that leaves the
liver parenchyma back to the central vein, a and p are
respective delay times of the arrival of artery bolus and por-
tal vein bolus to the liver parenchyma, and Hct is the small
vessel hematocrit. Total hepatic perfusion F is a sum of
hepatic arterial perfusion Fa and portal vein perfusion Fp
as
F = Fa + Fp = ka + kp/E , 2
where E is the extraction rate that is approximately equal to
1. In Eq. 1, hepatic arterial perfusion and portal vein per-
fusion are allowed to vary independently. K2 has also been
expressed as 1/MTT, where MTT is the mean transit time for
the blood or the contrast agent to travel through the sinusoid
and space of Disse and eventually to drain to the central
vein.
Perfusion parameters ka, kp, and K2 can be obtained
from mathematical fitting of the contrast concentration-time
curves associated with the aorta, portal vein, and liver paren-
chyma. We developed a numerical approach for estimation of
voxel-by-voxel liver perfusion, described in detail
elsewhere,14 which was used to estimate hepatic artery per-
fusion, portal vein perfusion, and the rate of blood outflow.
FIG. 1. Contrast concentration-time curves from artery diamond, portal
registration right. Time courses of signals after image registration right wIn brief, Eq. 1 is converted to
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0
t
Ca − ad + kp
0
t
Cp − pd
− 1 − HctK2
0
t
Cld 3
by taking an integral of Eq. 1. Note that the contrast con-
centration of liver parenchyma is linearly related to unknown
parameters of ka, kp, and K2. Therefore, a linear least squared
fit was used to estimate ka, kp, and K2 from Eq. 3. The
evaluation of this methodology is described in detail
elsewhere.14
Changes in the portal vein perfusion Fp and the outflow
rate K2 during and after RT were assessed in volumes of
interest VOIs of normal liver parenchyma, which extended
over the axial section to cover a large range of local radiation
dose levels for these conformal treatments. Each of the VOIs
was drawn in normal liver parenchyma that received similar
doses. Also, we excluded the clinical tumor volume, large
vessels, and the regions with motion artifacts from VOIs
Fig. 2. Within each of the VOIs, averaged portal vein per-
fusion Fp was calculated for each of the four perfusion
imaging sessions.
Statistical analysis
A multivariate linear regression analysis was performed to
determine covariances for prediction of percentage changes
in the regional portal vein perfusion one month after the
completion of RT vs prior to RT using SPSS SPSS Software
Products, INC, Chicago, IL. The tested variables included
the local dose accumulated at the end of RT and the percent-
age changes in portal vein perfusion after 1.5 weeks and
3 weeks of treatment. The correlation between the percent-
square, and liver parenchyma triangle before left and after image
used for fitting liver perfusion voxel-by-voxel.vein
ereage change in portal vein perfusion after 1.5 weeks and 3
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time of assessments was also tested. Similar analysis was
applied to the blood outflow rate.
RESULTS
Perfusion prior to, during, and after radiation therapy
We begin with evaluation of portal vein perfusion changes
over the course of RT and one month after the completion of
treatment. Doses received within normal liver VOIs at the
completion of RT varied from 11 to 78 Gy, with a median of
41 Gy, representing a wide range for evaluation of depen-
dency of perfusion changes on the regional total dose. A total
of 69 VOIs was obtained in the ten patients. The median
volume of VOIs was 1.0 cc, and ranged from 0.2 cc to
6.5 cc. The number of VOIs per patient varied from five to
nine, depending upon available normal liver parenchyma and
the dose extension in the scanned axial planes. The mean
portal vein perfusion of all VOIs had an initial value of
123.1±46.2 mean±SD ml/100 g/min prior to RT, and
changed little after 1.5 weeks of treatment
116.5±53.7 ml/100 g/min. However, after 3 weeks of
treatment 45 Gy delivered to the tumor, the average por-
tal vein perfusion decreased to 85.7±43.5 ml/100 g/min,
and decreased still further to 60.3±55.8 ml/100 g/min one
month after the completion of RT. These decreases in the
average portal vein perfusion values after receiving 3
weeks of treatment, and one month after the completion of
RT were statistically significant p0.001 and p0.0005,
respectively. Figure 3 shows an example of a reduction in
portal vein perfusion after the tumor received 46.5 Gy com-
pared to prior to RT. Figure 4 shows that the relationship
between portal vein perfusion and dose at the time of scan-
ning. After 1.5 weeks of treatment, regional portal vein
FIG. 2. Isodose curves and the clinical tumor volume CTV overlaid on a
CT liver slice. Volumes of interest in colors were drawn in the regions
beyond CTV and distributed over high to low doses.perfusion was not correlated with the local dose accumulated
Medical Physics, Vol. 34, No. 2, February 2007at the time of scanning p0.2. After 3 weeks of treat-
ment, correlation was significant p0.0001, with an esti-
mated slope of −1.6 ml/100 g/min per Gy. One month after
the completion of RT, the slope of the linear correlation
between portal vein perfusion and the accumulated dose
at the end of RT became steeper at an estimated
−2.5 ml/100 g/min per Gy.
Prediction of perfusion changes after radiation
therapy
Our goal was to determine if regional portal vein perfu-
sion changes one month after the completion of RT could be
predicted by the dose and by perfusion measured prior to RT
or during RT. First, we determined if the percentage change
in the regional portal vein perfusion one month after RT
compared to before treatment was predicted by the total dose
accumulated locally in a region of the liver at the end of RT.
We found that the percentage change in regional portal vein
perfusion one month after RT was linearly related to the local
accumulated liver dose at the end of RT with a coefficient of
−1.4% per Gy and the intercept restricted to be zero R2
=0.39, p0.0005. Next, we wished to determine whether
the change in perfusion measured after receiving approxi-
mately 3 weeks of radiation treatment approximately thirty
1.5 Gy treatment fractions or 45 Gy to the tumor was an
independent predictor of the portal vein perfusion one month
after the completion of RT. In fact, we found that both the
local liver dose at the end of RT and the percentage change
in regional portal vein perfusion after 45 Gy tumor dose
were significant and independent predictors for the percent-
age change in the regional portal vein perfusion one month
after completion of RT F=90.6, p0.00001, Table II and
Fig. 5. In a linear model fit with the two independent vari-
ables, the first predictor suggests that every Gy of local total
accumulated dose to the liver produced approximately a
1.2% reduction in the portal vein perfusion one month after
RT; and the second predictor suggests that individual patient
sensitivity that affects perfusion one month after treatment
can be assessed during the course of therapy Fig. 6. If there
was no individual dependency of perfusion changes after RT
FIG. 3. Portal vein perfusion maps prior to RT left and after the tumor
received 46.5 Gy right color-coded and overlaid on the liver axial CT. The
reduction in venous perfusion after 30 fractions of radiation can be visual-
ized in the color-coded venous perfusion images right. The greater de-
crease in venous perfusion was associated with the higher dose received.
Both images were windowed identically.upon measures during RT, the percentage changes in portal
ime e
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tracted by a product of a coefficient of −0.012 and dose at
the end of RT the dose contribution should be randomly
scattered around zero. However, Fig. 6 shows that the differ-
ence was linearly correlated with the percentage change in
portal vein perfusion after receiving 30 fractions of 1.5 Gy
treatment, indicating the extent of the perfusion changes dur-
ing RT influenced on the final extent of perfusion reduction
one month after the completion of RT. Finally, we tested
whether perfusion measured during the early course 1.5
weeks of radiation treatment could replace perfusion ob-
served during the late course 3 weeks of RT for predic-
tion of the portal vein perfusion one month following the
completion of RT. We found that perfusion observed after
receiving 1.5 weeks of radiation was also a predictor
p0.02 data not shown.
FIG. 4. Scattering plots of portal vein perfusion vs dose accumulated at th
treatment, and one month after the completion of RT right. The correlatio
of scanning became significant after 30 fractions of treatment. The slope
compared to after receiving 30 fractions of treatment, indicating there is a t
TABLE II. Model for prediction of reduction in portal
after the completion of radiation therapy. Fp%: the
after RT compared to the perfusion before RT; 1 mo
radiation treatment during which 30 fractions of 1.5
blood outflow rate K2=1/MTT during or after RT
time; B: coefficient; SE: standard error; t: t value.
Fp% 1 mon=B1*dosee
F=90.6, p0.000 01
Coefficients
Model B
dose end of RT −0.012
Fp% 3 wk 0.26
Model K2% 1 mon=B1*dosee
F=89.9, p0.000 01
Coefficients
B
dose end of RT −0.012
K2% 3 wk 0.35Medical Physics, Vol. 34, No. 2, February 2007Prediction of perfusion change during
radiation therapy
We further tested whether regional portal vein perfusion
changes during RT could be predicted by accumulated dose
to regions within the liver at the time of assessment. We
found that regional changes in portal vein perfusion mea-
sured after delivery of approximately 15 1.5 Gy fractions
22 Gy were not correlated with local accumulated liver
doses at the time of measurement r=0.06 and p0.5;
while after 30 fractions, the correlation between the regional
changes in portal vein perfusion and local accumulated doses
up to the time of measurement was significant r=0.24 and
p0.05. The percentage changes in portal vein perfusion
are positive in approximately 50% of data points after 15
fractions of radiation, and in approximately 30% of data
e of scanning after 15 fractions left and 30 fractions middle of 1.5 Gy
een regional portal vein perfusion and local dose accumulated at the time
e linear correlation was increased one month after the completion of RT,
ffect.
perfusion Fp or blood out flow rate K2 one month
entage change in the portal vein perfusion during or
e month after RT; 3 wk: after received 3 weeks of
ere received; K2%: the percentage change in the
ared to the perfusion before RT; MTT: mean transit
f RT+B2*Fp% 3 wk
t p
2 −10.10 0.0001
7 2.60 0.01
f RT+B2*K2% 3 wk
t p
1 −10.46 0.0001
8 3.58 0.0006e tim
n betw
of thvein
perc
n: on
Gy w
comp
nd o
SE
0.001
0.099
nd o
SE
0.001
0.097
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tients’ perfusion data, it was found that in 4 of 7 patients in
whom perfusion after 15 1.5 Gy fractions was available, por-
tal vein perfusion increased. These early increases in portal
vein perfusion transitioned to decreases after 30 fractions,
suggesting that it takes a certain amount of time for radiation
injury to occur in hepatic vasculature.
FIG. 5. A three-dimensional plot of the percentage change in the regional
portal vein perfusion one month after the completion of radiation therapy vs
the local accumulated liver dose at the end of radiation therapy and the
percentage change in portal vein perfusion after received 3 weeks of radia-
tion treatment 30 fractions of 1.5 Gy treatment. The central plane rep-
resents the multivariant linear regression fit, and the two outer planes depict
the 95% confidence interval.
FIG. 6. A scattering plot of the percentage changes in portal vein perfusion
one month after the completion of radiation therapy subtracted by a product
of B1 −0.012 and dose at the end of RT vs the percentage change in portal
vein perfusion after received 30 fractions of 1.5 Gy treatment. If there was
no individual variation in the radiation-induced venous perfusion reduction,
the data points should be scattered around the origin.
Medical Physics, Vol. 34, No. 2, February 2007Individual variations in perfusion changes after
radiation therapy
The extent of the portal vein perfusion changes in re-
sponse to radiation could depend upon individuals as indi-
cated by the observation that both regional liver doses at the
end of RT and changes in portal vein perfusion after receiv-
ing 3 weeks of radiation predicted the regional perfusion
changes one month after the completion of treatment. Two
examples two extreme cases are shown in Fig. 7. In one
patient left panel of Fig. 7 the percentage reduction in por-
tal vein perfusion one month after RT was found to be ap-
proximately 1.6% per Gy with a near zero intercept of the
fitted line, suggesting a relationship between dose and de-
crease in venous perfusion. In another case right panel of
Fig. 7, the percentage decrease in the venous perfusion was
approximately 3.4% per Gy while the intercept of the fitted
line with the axis representing the regional dose was
35 Gy, suggesting there were other factors that influenced
the venous perfusion response to radiation, possibly includ-
ing a floor effect of dose and time delay effect. In two of the
nine patients, a large positive intercept of the best fit line was
observed.
Prediction of MTT changes after radiation therapy
In parallel to the tests performed for the portal vein per-
fusion, we determined whether changes in the MTT one
month after radiation could be predicted by the total accu-
mulated dose in a region of the liver and by the MTT ob-
served before or during RT. In particular, we tested the per-
centage change in 1/MTT the rate of blood outflow or drain
to central vein one month after RT vs before treatment.
Similar to the findings in portal vein perfusion, the percent-
age changes in the regional 1/MTT one month after RT was
linearly predicted by the regional dose accumulated at the
end of RT and the percentage changes in the 1/MTT after 3
weeks of radiation treatment 45 Gy to the tumor F
=89.9, p0.00001, Table II.
Prediction of MTT changes during radiation therapy
We further tested whether regional changes in 1/MTT dur-
ing RT could be predicted by accumulated dose alone at the
time of assessment. We found that regional percentage
changes in 1/MTT measured after the tumor received 22 Gy
were not correlated with locally accumulated liver doses re-
ceived at the time of measurement r=0.05, p0.5, but the
correlation was significant after 45 Gy r=0.32 and p
0.01.
DISCUSSION
In this study, we found that the extent of the regional
reduction in the hepatic venous perfusion one month after RT
depended upon both the local accumulated dose at the end of
RT and the relative decrease in perfusion measured after de-
livery of approximately 30 fractions of 1.5 Gy radiation at
which point the tumors had received 45 Gy. As an average
over ten patients, every Gy of total dose delivered to liver
ts.
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proximately a 1% reduction in the venous perfusion one
month after completion of treatment. Furthermore, prediction
of the venous perfusion reduction for the group of the pa-
tients is improved by including the second predictor of the
venous perfusion measured after delivery of 45 Gy to the
tumor. The second predictor indicates that the extent of the
reduction in venous perfusion after RT varies from one per-
cent per Gy in individuals as shown in Figs. 5 and 6. The
venous perfusion measured after delivery of 22 Gy to tu-
mor might also be a predictor for the changes in venous
perfusion after RT. Furthermore, our analysis of the mean
transit time, which is derived independently from the DCE
data using a single compartmental model, supports the find-
ings regarding portal vein perfusion. This ability to predict
decreased perfusion one month after treatment by perfusion
measurements made during treatment is an important step
toward the ability to predict, and therefore avoid, RILD that
occurs after the completion of treatment.
Although liver changes following irradiation in cases with
or without RILD have been assessed previously by CT and
MRI,19–25 we believe this is the first quantitative report
studying the relationship between local radiation dose and
regional reduction in venous perfusion. Our preliminary data
suggest that a planned local liver dose and regional midtreat-
ment course hepatic venous perfusion model could be able to
determine individual liver tolerance to radiation during treat-
ment, thereby permitting individualization of the therapy
strategy. Our preliminary data enable a possible new para-
digm for studying and avoiding radiation toxicity in the liver.
We note that previous studies in other institutes have re-
ported dose effects on regional lung perfusion and ventilation
after irradiation.26–34 Some of the later studies attempted to
predict the degree of radiation-induced decline in pulmonary
FIG. 7. Scattering plots of the percentage changes in the regional portal vein
corresponding volumes of interest at the end of RT in two individual patienfunction after irradiation by using dose-response curves and
Medical Physics, Vol. 34, No. 2, February 2007dose-volume histograms.34 The general concepts described
by these studies could be applied to other parallel organs
such as liver. Here we expended the methodology for indi-
cation of whether liver function after irradiation might be
better predicted by assessments of function prior to the end
of radiation therapy.
In the past, efforts to develop models to estimate the like-
lihood of developing RILD have been based primarily on the
planned radiation dose distribution for the normal liver, ex-
pressed as a dose volume histogram.4,7–12 These models cur-
rently provide guidance for dose prescription and safe deliv-
ery of doses to the liver. However, individual patient
sensitivity to radiation is not reflected by predictions made
solely based on the physical dose distribution and the patient
population data. Many studies have attempted to identify
clinical and patient-specific factors, and biological and ge-
netic markers for prediction of individual sensitivity to radia-
tion. One of our own analyses of incidences of RILD using a
normal tissue complication probability NTCP model re-
veals that the susceptibility to RILD is different between
patients who have metastases and primary liver tumors.9 This
finding has been used to further customize in-house models
for dose prescription based on a predicted 10–15% NTCP. In
another study, a multivariate analysis identified infection
with hepatitis B virus, as well as presence of Child-Pugh B
cirrhosis as factors that increased the incidence of RILD in
patients treated with three-dimensional conformal radio-
therapy for hepatocellular carcinoma.35,36 These clinical fac-
tors provide information on preexisting conditions that influ-
ence tolerance of subgroups of patients to radiation.
However, individual tolerance to radiation may be influenced
beyond these factors that have been identified, and is likely
to be both genetic and environmental. Although the identifi-
cation of the genetic basis of RILD is of fundamental inter-
sion one month after radiation therapy vs the local dose accumulated for theperfuest, this approach faces substantial challenges due to the fact
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tiple genes. Therefore, we have attempted to develop an ap-
proach that utilizes anatomically resolved perfusion before
and during RT, and combines it with the radiation treatment
plan to predict the radiation toxicity in the liver.
This study has some limitations. Most importantly, we
estimated hepatic perfusion in a single slab 2 cm of liver
using DCE CT. This limited spatial coverage of the liver
restricts us in relating what we found in the single slab to the
whole liver. Thus, additional work will be required to estab-
lish the relationship between decreases in hepatic perfusion
as measured in this study and both overall liver function and
RILD. In order to carry out such analyses, we will need to
develop a model of applying the changes in perfusion mea-
sured in the 2 cm slab to the remainder of the liver, presum-
ably by using the full liver three-dimensional dose distribu-
tion. This limitation can be overcome by using volumetric
DCE MRI with the parallel imaging technology that can im-
prove the imaging speed by several factors. In addition,
given that we could sample only a limited number of time
points, it is difficult to fully analyze potentially important
factors such as the role of fraction size and the time after
received the dose. We did attempt to apply an  / ratio of
2.5 to correct the fraction size effect,37 which did not lead to
an improvement in the correlation between the local dose
and the regional venous perfusion change measured during
treatment data not shown. When inspecting individual pa-
tients’ perfusion data we observed that, in 4 of 7 patients data
in whom perfusion after approximately 1.5 weeks of radia-
tion treatment were available, the venous perfusion in-
creased. Thereafter, the venous perfusion started decreasing
but the rate and the extent of the decreases varied greatly
with individuals. Finally, one month after the completion of
RT the direction and the extent of the venous perfusion
changes became more predictable than during treatment.
These observations suggest that in addition to individual sen-
sitivity to dose there are great individual variations in the
time to respond to radiation. Additional patients will need to
be accrued to better quantify these relationships.
CONCLUSION
In this study, we demonstrated a possible new strategy to
investigate radiation toxicity in the liver. Our preliminary
data show that the reduction in regional hepatic venous per-
fusion after RT is predictable by the local accumulated liver
dose and venous perfusion measured prior to end of RT. This
local hepatic-perfusion injury model has the potential to pre-
dict symptomatic radiation damage to the liver.
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